SOLIGENIX, INC. Proceeds from Issuance or Sale of Equity
SOLIGENIX, INC. (SNGX) reported Proceeds from Issuance or Sale of Equity of $1.94 million for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2016-03-24
- SOLIGENIX, INC. proceeds from issuance or sale of equity for the quarter ending 2013-12-31 was -$6.22K.
- SOLIGENIX, INC. proceeds from issuance or sale of equity for the quarter ending 2013-09-30 was $0.00.
- SOLIGENIX, INC. proceeds from issuance or sale of equity for fiscal 2014 was $1.94M, a 68.80% decline from fiscal 2013.
- SOLIGENIX, INC. proceeds from issuance or sale of equity for fiscal 2013 was $6.21M.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month | Proceeds from Issuance or Sale of Equity 12 month as first filed |
|---|---|---|---|---|---|
| 2014-12-31 | $1.94M 10-K · filed 2016-03-24 | ||||
| 2013-12-31 | -$6.22K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-25 | -$6.22K derived: sum of 2 quarters · filed 2015-03-25 | $6.21M 10-K · filed 2015-03-25 | $71.95K 10-K · filed 2014-03-26 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $6.22M 10-Q · filed 2014-11-10 | |||
| 2013-06-30 | $6.22M 10-Q · filed 2014-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |